Dimension Secures $500M for Biotech and AI Convergence Fund
TL;DR Summary
Dimension, a venture capital firm, has successfully raised a $500 million second fund to invest in the intersection of biotechnology and machine learning, an area they describe as 'still contrary.' The firm, led by managing partners in New York and the Bay Area, aims to capitalize on the growing synergy between biological sciences and AI technologies.
- Dimension nabs $500M second fund for 'still contrary' intersection of bio and machine learning Endpoints News
- VC firm raises $500 million for fund aimed at intersection of tech and life sciences Axios
- Dimension gets $500M to bankroll biotech’s convergence with tech BioPharma Dive
- Young biotech venture firm raises $500 million for its second fund STAT
- VC Firm Dimension Raises $500 Million to Bet on AI and Medicine Bloomberg
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
39%
92 → 56 words
Want the full story? Read the original article
Read on Endpoints News